No abstract

n=24/30, 80%). Clinician-reported vitiligo body surface area (BSA) involvement ranged from 4-70% overall (90% adolescents and 30% adults with BSA= 4-20%) The VitiQoL 2.0 was generally well received, with participants reporting high levels of item understanding (n=29/30, 96%), as well as suitability of response options (n=29/ 30, 96%) and of the modified recall period (n=28/30, 93%). Most adults (n=17/20, 85%) and adolescents (n=6/10, 60%) reported that the items were relevant. For two items (3: effect on showing affection; 6: fear of others finding fault), 50% of participants found the concepts relevant and nearly all understood the items, but interpretations were inconsistent. Conclusions: While the VitiQoL 2.0 adequately captured the impacts of vitiligo in adults, it had limited conceptual relevance among adolescents. This was possibly due to lower average BSA involvement among adolescent participants who were therefore less likely to experience similar disease impact. With minor modifications, the VitiQoL 2.0 may be suitable to capture patients' perspective of disease impact in vitiligo clinical trials.